Proteros has entered multiple collaborations with big pharma to discover and develop novel in vivo active lead compounds against several epigenetic targets for the treatment of various types of cancer and is seeking further partnerships in this specific area.
Proteros´ epigenetic platform has been validated through years of successful application and multiple big pharma collaborations.
In 2015, a discovery collaboration with Merck Sharp & Dohme Corp. (MSD) was established, in which MSD gained access to Proteros’ proprietary NEATTM engine and structure-guided discovery platform for an undisclosed epigenetic target in oncology, representing an exciting and promising new approach to the cancer clinical research landscape. Proteros holds responsibility for the design of lead compounds. MSD will be responsible for the development, manufacturing and commercialization of clinical lead molecules.
In 2016, Proteros entered into a second discovery collaboration with Merck Sharp & Dohme Corp. (MSD). The new collaboration is aimed at developing small molecule compounds against an additional epigenetic target for the potential treatment of various cancers.
In 2017, Proteros entered into a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, focusing on a sub-class of technically complex epigenetic targets to identify quality lead compounds.
Proteros’ proprietary lead discovery technology gained validation in May 2013 through the asset-centric financing of an in-house epigenetic project with Atlas Venture and Johnson & Johnson Development Corporation (JJDC), which led to the creation of a Joint Venture, Rodin Therapeutics Inc. Rodin’s foundation was based on new insights into key epigenetic HDAC modulators of central nervous system (CNS) function, privileged access to Proteros' best-in-class structural biology capabilities and a team with deep CNS drug development expertise.
About 12 months after the seed financing, Rodin’s progress led to the closing of a $12.9 million Series A financing by investors Atlas Venture and JJDC in May 2014. Funding was used to propel the work through lead optimization to preclinical Proof-of-Concept in Alzheimer’s disease and to finance expansion into additional epigenetic modulators focusing on the improvement of cognitive function.
In 2016, the Rodin Joint Venture signed an agreement with Biogen, committed to a financing of US $17 million and a multi-year research collaboration to develop novel therapeutics for neurological disorders. Additionally, Biogen secured the option to acquire Rodin for up to US $485 million including total upfront and milestone payments.